PT3678644T - Formulações de copanlisib - Google Patents

Formulações de copanlisib

Info

Publication number
PT3678644T
PT3678644T PT187621073T PT18762107T PT3678644T PT 3678644 T PT3678644 T PT 3678644T PT 187621073 T PT187621073 T PT 187621073T PT 18762107 T PT18762107 T PT 18762107T PT 3678644 T PT3678644 T PT 3678644T
Authority
PT
Portugal
Prior art keywords
copanlisib
formulations
Prior art date
Application number
PT187621073T
Other languages
English (en)
Original Assignee
Bayer Consumer Care Ag
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Consumer Care Ag, Bayer Pharma AG filed Critical Bayer Consumer Care Ag
Publication of PT3678644T publication Critical patent/PT3678644T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PT187621073T 2017-12-15 2018-09-06 Formulações de copanlisib PT3678644T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17207771.1A EP3498266A1 (en) 2017-12-15 2017-12-15 Formulations of copanlisib

Publications (1)

Publication Number Publication Date
PT3678644T true PT3678644T (pt) 2023-07-25

Family

ID=60781613

Family Applications (1)

Application Number Title Priority Date Filing Date
PT187621073T PT3678644T (pt) 2017-12-15 2018-09-06 Formulações de copanlisib

Country Status (3)

Country Link
EP (1) EP3498266A1 (pt)
EA (1) EA202090568A1 (pt)
PT (1) PT3678644T (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112569340A (zh) * 2020-12-31 2021-03-30 苏州素仕生物科技有限公司 一种无菌布舍瑞林注射液及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2312843T3 (es) 2002-09-30 2009-03-01 Bayer Healthcare Ag Derivados de azolpirimidina condensados.
AR064106A1 (es) 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
EP2508525A1 (en) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
EP3018127A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
BR112018015783A2 (pt) * 2016-02-01 2018-12-26 Bayer Pharma AG biomarcadores de copanlisibe

Also Published As

Publication number Publication date
EA202090568A1 (ru) 2020-07-08
EP3498266A1 (en) 2019-06-19

Similar Documents

Publication Publication Date Title
IL273541A (en) formulations
IL268697A (en) Formulations
IL269630A (en) Niraprib formulations
IL269621A (en) Niraparib formulations
IL273282A (en) Niraprib formulations
IL265609A (en) New formulations
GB201607918D0 (en) Novel formulations
IL269409A (en) Combinations of chk1- and wee1 - inhibitors
IL274627A (en) Solid forms of valbenazine
LT3943070T (lt) Ilgo veikimo bedakvilino preparatai
IL272857A (en) Cofanalisib formulations
GB201707189D0 (en) Novel formulations
GB201707188D0 (en) Novel formulations
IL267279A (en) Pharmaceutical formulations of suvorexant
GB201707187D0 (en) Novel formulations
PT3678644T (pt) Formulações de copanlisib
IL268195A (en) Solid fosmetpantothenate formulations
GB201721386D0 (en) Chrondogy of time-wave
GB201714461D0 (en) Formulations
GB201716291D0 (en) Novel formulations
GB201707562D0 (en) Novel formulations
GB201707564D0 (en) Novel formulations
GB201707190D0 (en) Novel Formulations
GB201716293D0 (en) Novel formulations of aprepitant
GB201621277D0 (en) Formulations